{"id":68772,"date":"2026-02-21T15:51:18","date_gmt":"2026-02-21T15:51:18","guid":{"rendered":"https:\/\/medsbase.com\/?post_type=product&#038;p=68772"},"modified":"2026-10-15T10:21:51","modified_gmt":"2026-10-15T10:21:51","slug":"retatrutide","status":"publish","type":"product","link":"https:\/\/medsbase.com\/pt-pt\/product\/retatrutide\/","title":{"rendered":"Retatrutide"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background: #fff8e1; border-left: 4px solid #f5a623; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<h3 style=\"margin: 0 0 8px 0; font-size: 16px; color: #1a4a6b;\">Resposta R\u00e1pida \u2014 O que \u00e9 o Retatrutide?<\/h3>\n<p style=\"margin: 0;\">Retatrutide (LY3437943) is a peptide and the first <strong>agonista triplo de recetores<\/strong> que atua simultaneamente nos recetores GLP-1, GIP e glucagon numa \u00fanica mol\u00e9cula. Nos ensaios de fase 2 (Jastreboff 2023, NEJM), produziu uma redu\u00e7\u00e3o m\u00e9dia de peso de <strong>24,2% \u00e0s 48 semanas<\/strong> \u2014 higher than any other published metabolic peptide to date. Available in 5\u00a0mg to 60\u00a0mg lyophilized vials.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background: #f4f8fb; border: 1px solid #d8e3eb; padding: 12px 16px; margin: 16px 0; border-radius: 4px; font-size: 14px;\"><strong>O que obt\u00e9m com a MedsBase:<\/strong> Pharmaceutical-grade lyophilized peptides &middot; HPLC &ge;99% purity (COA on request) &middot; Discreet protective packaging &middot; Worldwide peptide courier &middot; 1,400+ verified <a href=\"https:\/\/medsbase.com\/pt-pt\/reviews\/\">de clientes<\/a><\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size: 14px; color: #444; margin: 8px 0 18px;\">\ud83d\udce6 Cada encomenda est\u00e1 coberta pela nossa <a href=\"https:\/\/medsbase.com\/pt-pt\/medsbase-re-shipment-assurance-policy\/\"><strong>Pol\u00edtica de Garantia de Reenvio<\/strong><\/a> \u2014 se a sua encomenda n\u00e3o chegar no prazo de 20 dias \u00fateis, reenviamo-la.<\/p>\n<table class=\"medsbase-spec-table\" style=\"width: 100%; border-collapse: collapse; margin: 18px 0; font-size: 14px;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 8px 12px; text-align: left; width: 30%;\">Especifica\u00e7\u00e3o<\/th>\n<th style=\"padding: 8px 12px; text-align: left;\">Detalhe<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>N\u00famero CAS<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">2381089-83-2<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>F\u00f3rmula Molecular<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">C<sub>221<\/sub>H<sub>342<\/sub>N<sub>46<\/sub>O<sub>68<\/sub><\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Peso Molecular<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">~4731,4 Da<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Sequ\u00eancia<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Agonista triplo modificado de GIP\/GLP-1\/GCGR (39 res\u00edduos, lipidado; LY-3437943 propriet\u00e1rio da Lilly)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Forma<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">P\u00f3 liofilizado (ou conforme fornecido)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Pureza<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u226599% (HPLC verificado, COA dispon\u00edvel mediante pedido)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Armazenamento<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Liofilizado: 2\u20138 \u00b0C (frigor\u00edfico) para stock de trabalho; \u221220 \u00b0C para armazenamento a longo prazo de frascos n\u00e3o abertos. Reconstitu\u00eddo: 2\u20138 \u00b0C, utilizar no prazo de ~30 dias. Proteger da luz. N\u00e3o congelar-descongelar a solu\u00e7\u00e3o reconstitu\u00edda.<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Solubilidade<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u00c1gua bacteriost\u00e1tica (recomendada) ou \u00e1gua est\u00e9ril para per\u00edodos de utiliza\u00e7\u00e3o mais curtos<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><!-- \/medsbase-tldr-answer --><\/p>\n<h2>O que \u00e9 o Retatrutide<\/h2>\n<p><strong>Retatrutide<\/strong> (designa\u00e7\u00e3o em investiga\u00e7\u00e3o <strong>LY3437943<\/strong>) is a synthetic 39-amino-acid peptide developed by Eli Lilly as the first clinical-stage triple agonist of the GLP-1, GIP, and glucagon receptors. Where earlier incretin peptides act on one receptor (semaglutide \u2014 GLP-1) or two (tirzepatide \u2014 GLP-1 plus GIP), retatrutide engages all three metabolic receptors simultaneously. This distinct pharmacology is being studied for obesity, type 2 diabetes, non-alcoholic fatty liver disease (NAFLD\/MASH), and hypertension-linked metabolic syndrome. The peptide has a molecular weight of approximately 4,731.4\u00a0Da, empirical formula C<sub>221<\/sub>H<sub>342<\/sub>N<sub>46<\/sub>O<sub>68<\/sub>, and is supplied as a high-purity lyophilized powder for reconstitution with bacteriostatic water. For deeper mechanism, trial, and outlook detail, see our full <a href=\"https:\/\/medsbase.com\/pt-pt\/retatrutide-triple-agonist-weight-loss-guide\/\">Retatrutide guide<\/a>. <\/p>\n<h2>Mecanismo de A\u00e7\u00e3o \u2014 Agonista Triplo GLP-1\/GIP\/Glucagon<\/h2>\n<p>O perfil de recetores do Retatrutide \u00e9 o que o diferencia de todos os outros pept\u00eddeos metab\u00f3licos atualmente no mercado ou em ensaios em fase avan\u00e7ada. Cada um dos tr\u00eas recetores contribui com uma via distinta para os efeitos observados na composi\u00e7\u00e3o corporal, controlo da glucose e equil\u00edbrio energ\u00e9tico:<\/p>\n<ul>\n<li><strong>Recetor GLP-1<\/strong> \u2014 o mesmo recetor ativado pela semaglutida (Ozempic, Wegovy) e pela liraglutida. A agoniza\u00e7\u00e3o retarda o esvaziamento g\u00e1strico, melhora a sinaliza\u00e7\u00e3o de saciedade no hipot\u00e1lamo e estimula a secre\u00e7\u00e3o de insulina dependente da glucose pelas c\u00e9lulas beta pancre\u00e1ticas.<\/li>\n<li><strong>Recetor GIP<\/strong> \u2014 a segunda via adicionada pela tirzepatida (Mounjaro, Zepbound). A agoniza\u00e7\u00e3o do GIP melhora a sensibilidade \u00e0 insulina no tecido adiposo, reduz o limite de n\u00e1useas do GLP-1 isolado e apoia a efici\u00eancia do manuseio de l\u00edpidos pelos adip\u00f3citos.<\/li>\n<li><strong>Recetor de glucagon<\/strong> \u2014 a terceira via inovadora, exclusiva do retatrutide. A agoniza\u00e7\u00e3o do glucagon aumenta o gasto energ\u00e9tico basal, promove a oxida\u00e7\u00e3o de l\u00edpidos hep\u00e1ticos e reduz a gordura do f\u00edgado \u2014 efeitos que a dupla GLP-1\/GIP n\u00e3o reproduz.<\/li>\n<\/ul>\n<p>Because increased energy expenditure via glucagon stacks additively on top of the appetite suppression driven by GLP-1\/GIP, retatrutide produces both a larger energy deficit and a more favourable body-composition profile in preclinical models than dual-agonist peptides. In phase 2 data, fat-mass loss accounted for the majority of total weight reduction, with preserved lean mass in the higher dose arms. <\/p>\n<h2>Dados de Ensaios Publicados<\/h2>\n<p>O conjunto de dados principais do retatrutide \u00e9 o ensaio de obesidade da fase 2 publicado por Jastreboff e colegas na <em>New England Journal of Medicine<\/em> em junho de 2023 (n=338 participantes com obesidade, per\u00edodo de tratamento de 48 semanas). Na dose mais elevada testada de 12 mg semanais, os participantes apresentaram uma redu\u00e7\u00e3o m\u00e9dia de peso corporal de <strong>24,2% em rela\u00e7\u00e3o \u00e0 linha de base<\/strong>. The comparator semaglutide arm in the STEP-1 trial produced 14.9% reduction at 68 weeks and the tirzepatide arm in SURMOUNT-1 produced 22.5% at 72 weeks \u2014 so retatrutide achieved a numerically larger reduction in a shorter treatment window. Head-to-head comparative trials have not yet been published. A parallel phase 2 diabetes programme (Rosenstock et al., <em>Lancet<\/em> 2023) demonstrated HbA1c reductions of up to 2.16 percentage points at 36 weeks in participants with type 2 diabetes, again at the 12\u00a0mg weekly dose. A phase 2 NAFLD sub-study reported a 51.3% relative reduction in liver-fat content after 24 weeks at the 8\u00a0mg dose \u2014 the largest liver-fat reduction reported for any incretin-class peptide to date. Eli Lilly is currently running the TRIUMPH phase 3 programme, including <strong>TRIUMPH-1<\/strong> (obesidade), <strong>TRIUMPH-2<\/strong> (obesidade com diabetes tipo 2), <strong>TRIUMPH-3<\/strong> (obesidade com doen\u00e7a cardiovascular), e <strong>TRIUMPH-4<\/strong> (apneia do sono mais obesidade). Espera-se que os resultados da Fase 3 informem a eventual submiss\u00e3o regulat\u00f3ria. <\/p>\n<h2>Published Evidence<\/h2>\n<p>Retatrutide is used in clinical contexts that investigate:<\/p>\n<ul>\n<li><strong>Obesidade e regula\u00e7\u00e3o do peso corporal<\/strong> \u2014 trabalho mecan\u00edstico sobre sinaliza\u00e7\u00e3o do apetite, cin\u00e9tica de esvaziamento g\u00e1strico e gasto energ\u00e9tico em modelos de roedores e in vitro<\/li>\n<li><strong>Sensibilidade \u00e0 insulina e homeostase da glucose<\/strong> \u2014 efeitos na secre\u00e7\u00e3o de insulina, produ\u00e7\u00e3o hep\u00e1tica de glucose e elimina\u00e7\u00e3o perif\u00e9rica de glucose<\/li>\n<li><strong>Esteatose hep\u00e1tica \/ MASH<\/strong> \u2014 liver fat mobilisation and transaminase response in fatty-liver study models<\/li>\n<li><strong>Farmacologia dos recetores<\/strong> \u2014 estudos comparativos de liga\u00e7\u00e3o, seletividade e sinaliza\u00e7\u00e3o descendente atrav\u00e9s do trio de recetores GLP-1\/GIP\/glucagon<\/li>\n<li><strong>Comparative metabolic-peptide studies<\/strong> \u2014 benchmarking em rela\u00e7\u00e3o ao tirzepatide (agonista duplo GLP-1\/GIP) e outros compostos investigacionais quanto \u00e0 pot\u00eancia, tolerabilidade e resultados na composi\u00e7\u00e3o corporal. Consulte a nossa <a href=\"https:\/\/medsbase.com\/pt-pt\/tirzepatide-tirzepatide-vs-semaglutide\/\">compara\u00e7\u00e3o entre tirzepatide e semaglutide<\/a> para a linha de base do agonista duplo.<\/li>\n<li><strong>Empilhamento de pept\u00eddeos para cura e recupera\u00e7\u00e3o<\/strong> \u2014 protocols that pair metabolic peptides with repair compounds such as <a href=\"https:\/\/medsbase.com\/pt-pt\/bpc-157\/\">BPC-157<\/a> em estudos pr\u00e9-cl\u00ednicos.<\/li>\n<\/ul>\n<p>Para um contexto mais amplo sobre onde o retatrutide se enquadra no cen\u00e1rio de pept\u00eddeos para perda de peso, consulte o nosso <a href=\"https:\/\/medsbase.com\/pt-pt\/peptide-stacks-for-fat-loss\/\">peptide stacks for fat loss guide<\/a> e o <a href=\"https:\/\/medsbase.com\/pt-pt\/glp-1-weight-loss-injections-guide\/\">guia geral de inje\u00e7\u00f5es para perda de peso com GLP-1<\/a>. Navegue pelo <a href=\"https:\/\/medsbase.com\/pt-pt\/peptides\/\">cat\u00e1logo de p\u00e9ptidos<\/a> para encontrar compostos relacionados. <\/p>\n<h2>For\u00e7as e Concentra\u00e7\u00f5es Dispon\u00edveis<\/h2>\n<p>MedsBase stocks retatrutide in the following lyophilized vial sizes. Each variation is supplied in 10-vial, 20-vial, and 30-vial pack formats, shipped under chilled conditions with reconstitution instructions:<\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">For\u00e7a do frasco<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Caso de uso t\u00edpico<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Tamanhos das embalagens<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>5\u00a0mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Estudos de dosagem piloto, rampa de titula\u00e7\u00e3o<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 frascos<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>10\u00a0mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Standard strength, most commonly ordered<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 frascos<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>15\u00a0mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Dose experimental correspondente (bra\u00e7o de dose elevada da fase 2)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 frascos<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>20 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Extended protocols, bulk preparation<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 frascos<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>30 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Bulk packs (fewer reconstitutions per protocol)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 frascos<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>40 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">High-throughput studies, cost-per-mg optimisation<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 frascos<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>50 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Large-batch clinical use<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 frascos<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>60 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Maximum bulk option, longest-duration studies<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 frascos<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Todas as dosagens s\u00e3o fornecidas na mesma forma qu\u00edmica (p\u00f3 liofilizado, pureza \u226599% por HPLC). Os frascos com maior dosagem oferecem um custo por mg mais baixo, mas requerem volumes de reconstitui\u00e7\u00e3o menores para manter as concentra\u00e7\u00f5es padr\u00e3o de seringa U-100 \u2014 consulte a tabela de dilui\u00e7\u00e3o abaixo. <\/p>\n<h2>Compara\u00e7\u00e3o \u2014 Retatrutida vs Tirzepatida vs Semaglutida<\/h2>\n<p>O seguinte resumo baseia-se em dados de ensaios publicados. A Retatrutida ainda est\u00e1 em desenvolvimento na fase 3 e as compara\u00e7\u00f5es abaixo s\u00e3o entre estudos separados, n\u00e3o cabe\u00e7a-a-cabe\u00e7a. <\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Crit\u00e9rio<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Retatrutide<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Tirzepatide<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Semaglutide<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Alvos dos recetores<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">GLP-1 + GIP + Glucagon (triplo)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">GLP-1 + GIP (duplo)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">GLP-1 (\u00fanico)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Perda de peso m\u00e1xima publicada<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">24,2% \u00e0s 48 semanas<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">22,5% \u00e0s 72 semanas<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">14,9% \u00e0s 68 semanas<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Frequ\u00eancia de dosagem<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Semanal<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Semanal<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Semanal<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Estado regulamentar<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Fase 3 (TRIUMPH) \u2014 investigacional<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Aprovado pela FDA (Mounjaro\/Zepbound)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Aprovado pela FDA (Ozempic\/Wegovy)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Redu\u00e7\u00e3o de gordura hep\u00e1tica<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">51,3% \u00e0s 24 semanas (fase 2)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~47% \u00e0s 52 semanas<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~31% \u00e0s 72 semanas<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Redu\u00e7\u00e3o de HbA1c (DM2)<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">At\u00e9 -2,16% \u00e0s 36 semanas<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">At\u00e9 -2,3% \u00e0s 40 semanas<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">At\u00e9 -1,8% \u00e0s 40 semanas<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Para uma compara\u00e7\u00e3o mais aprofundada entre tirzepatida e semaglutida especificamente, consulte <a href=\"https:\/\/medsbase.com\/pt-pt\/tirzepatide-tirzepatide-vs-semaglutide\/\">Tirzepatida vs Semaglutida: Perda de Peso, Dosagem e Custo<\/a>. <\/p>\n<h2>Armazenamento e Reconstitui\u00e7\u00e3o<\/h2>\n<p><strong>Antes da reconstitui\u00e7\u00e3o:<\/strong> armazene os frascos liofilizados refrigerados a 2\u20138 \u00b0C na embalagem de folha original. Nestas condi\u00e7\u00f5es, o retatrutida liofilizado mant\u00e9m-se est\u00e1vel at\u00e9 36 meses. Evite ciclos repetidos de temperatura. <strong>Procedimento de reconstitui\u00e7\u00e3o:<\/strong> adicione \u00e1gua bacteriost\u00e1tica ao frasco do p\u00e9ptido de acordo com a tabela de dilui\u00e7\u00e3o acima. Injete a \u00e1gua pela parede lateral do frasco em vez de diretamente sobre o p\u00f3 liofilizado. Agite suavemente \u2014 n\u00e3o <strong>n\u00e3o<\/strong> sacuda \u2014 e deixe repousar 5\u201310 minutos para dissolu\u00e7\u00e3o completa. Uma solu\u00e7\u00e3o totalmente reconstitu\u00edda deve ser l\u00edmpida e incolor. <strong>Ap\u00f3s reconstitui\u00e7\u00e3o:<\/strong> armazene a solu\u00e7\u00e3o refrigerada a 2\u20138 \u00b0C e utilize-a no prazo de 30 dias para uma estabilidade \u00f3tima. N\u00e3o congele a solu\u00e7\u00e3o reconstitu\u00edda \u2014 os ciclos de congela\u00e7\u00e3o-descongela\u00e7\u00e3o degradam a integridade do p\u00e9ptido. Descarte qualquer frasco que apresente turva\u00e7\u00e3o, precipitado ou descolora\u00e7\u00e3o. <\/p>\n<h2 id=\"faqs\">Perguntas Frequentes<\/h2>\n<h3>What is retatrutide used for in studies?<\/h3>\n<p>Retatrutide is used in studies investigating obesity, type 2 diabetes, non-alcoholic fatty liver disease (NAFLD\/MASH), insulin sensitivity, appetite regulation, and comparative metabolic-peptide pharmacology. It is <strong>n\u00e3o<\/strong> approved by the FDA, EMA, or other regulators for human therapeutic use and is sold here strictly for clinical studies use only. <\/p>\n<h3>Em que \u00e9 que o retatrutida difere do tirzepatida e do semaglutida?<\/h3>\n<p>O retatrutida \u00e9 o primeiro agonista triplo de recetores, ligando-se aos recetores de GLP-1, GIP e, <em>e<\/em> glucagon numa \u00fanica mol\u00e9cula. O tirzepatida liga-se ao GLP-1 e ao GIP (duplo). O semaglutida liga-se apenas ao GLP-1 (simples). A via adicional do glucagon no retatrutida aumenta o gasto energ\u00e9tico e reduz a gordura hep\u00e1tica de formas que os agonistas duplos e simples n\u00e3o reproduzem. <\/p>\n<h3>Que perda de peso foi demonstrada pelo retatrutida em ensaios?<\/h3>\n<p>O ensaio de fase 2 sobre obesidade publicado por Jastreboff et al. no NEJM (2023) reportou uma redu\u00e7\u00e3o m\u00e9dia de peso corporal de 24,2% \u00e0s 48 semanas na dose mais elevada testada de 12 mg semanal. Para contexto, o bra\u00e7o de dose mais elevada do tirzepatida na fase 3 produziu 22,5% \u00e0s 72 semanas e o do semaglutida produziu 14,9% \u00e0s 68 semanas. Os resultados do retatrutida na fase 3 do programa TRIUMPH est\u00e3o pendentes. <\/p>\n<h3>O retatrutide foi aprovado pela FDA?<\/h3>\n<p>No. Retatrutide is currently in phase 3 clinical development under Eli Lilly&#8217;s TRIUMPH programme and has not received regulatory approval from the FDA, EMA, MHRA, or any other authority. <\/p>\n<h3>Que dosagens est\u00e3o dispon\u00edveis na MedsBase?<\/h3>\n<p>MedsBase carries retatrutide in 5\u00a0mg, 10\u00a0mg, 15\u00a0mg, 20\u00a0mg, 30\u00a0mg, 40\u00a0mg, 50\u00a0mg, and 60\u00a0mg lyophilized vials. Each strength is available in 10-vial, 20-vial, or 30-vial pack sizes. All vials are supplied at 99%+ HPLC purity with a certificate of analysis on request. <\/p>\n<h3>Como devo reconstituir o retatrutide?<\/h3>\n<p>Siga o gr\u00e1fico de dilui\u00e7\u00e3o acima. Um frasco de 10\u00a0mg com 2,0\u00a0mL de \u00e1gua bacteriost\u00e1tica resulta numa concentra\u00e7\u00e3o de 5,0\u00a0mg\/mL, pelo que 40 marcas numa seringa de insulina U-100 (1\u00a0mL \/ 100 unidades) equivalem a 2\u00a0mg. Injete a \u00e1gua BAC pela parede lateral, agite suavemente (n\u00e3o agite vigorosamente) e deixe dissolver durante 5\u201310 minutos antes de usar. <\/p>\n<h3>Como deve ser armazenado o retatrutide?<\/h3>\n<p>Frascos liofilizados: refrigerados a 2\u20138\u00a0\u00b0C na embalagem original, est\u00e1veis at\u00e9 36 meses. Solu\u00e7\u00e3o reconstitu\u00edda: refrigerada a 2\u20138\u00a0\u00b0C, utilizar no prazo de 30 dias. N\u00e3o congele a solu\u00e7\u00e3o reconstitu\u00edda \u2014 ciclos de congela\u00e7\u00e3o e descongela\u00e7\u00e3o degradam o pept\u00eddeo. <\/p>\n<h3>What is the typical dose of retatrutide in studies?<\/h3>\n<p>Phase 2 obesity-trial arms tested 1\u00a0mg, 4\u00a0mg, 8\u00a0mg, and 12\u00a0mg weekly doses over 48 weeks. Weight-loss response was dose-dependent, with 24.2% reduction observed at the 12\u00a0mg arm. Clinical protocols typically mirror these trial doses when the intent is to model published efficacy data. <\/p>\n<h3>O retatrutide causa os mesmos efeitos secund\u00e1rios que outros pept\u00eddeos GLP-1?<\/h3>\n<p>Nos ensaios publicados, os eventos adversos mais comuns foram efeitos gastrointestinais dose-dependentes \u2014 n\u00e1useas, diarreia, obstipa\u00e7\u00e3o \u2014 semelhantes ao perfil do semaglutide e do tirzepatide. A atividade adicional no recetor de glucagon n\u00e3o produziu sinais de seguran\u00e7a inesperados na fase 2, mas o perfil completo de tolerabilidade aguarda os resultados da fase 3. <\/p>\n<h3>Quanto tempo at\u00e9 o retatrutide ser aprovado pela FDA?<\/h3>\n<p>O programa de fase 3 TRIUMPH da Eli Lilly come\u00e7ou a recrutar em 2023\u20132024, com datas de conclus\u00e3o prim\u00e1ria projetadas para 2025\u20132027, dependendo do sub-ensaio. Assumindo resultados positivos, uma submiss\u00e3o \u00e0 FDA poder\u00e1 ocorrer 12\u201318 meses ap\u00f3s a conclus\u00e3o prim\u00e1ria. Os prazos de aprova\u00e7\u00e3o regulamentar s\u00e3o especulativos at\u00e9 que a Lilly anuncie o pedido. <\/p>\n<h3>Qual \u00e9 a meia-vida do retatrutide?<\/h3>\n<p>O Retatrutide (LY3437943) tem uma meia-vida de elimina\u00e7\u00e3o longa de aproximadamente 6 dias nos dados cl\u00ednicos da Fase I, atribu\u00edda \u00e0 modifica\u00e7\u00e3o com \u00e1cido gordo C18 que permite a liga\u00e7\u00e3o \u00e0 albumina. Esta meia-vida prolongada suporta esquemas posol\u00f3gicos semanais utilizados nos ensaios cl\u00ednicos. <\/p>\n<h3>Como \u00e9 que o Retatrutide se compara ao Tirzepatide e ao Semaglutide?<\/h3>\n<p>O Retatrutide \u00e9 um agonista triplo (receptores GLP-1\/GIP\/Glucagon), em compara\u00e7\u00e3o com o agonismo duplo do Tirzepatide (GLP-1\/GIP) e o agonismo \u00fanico GLP-1 do Semaglutide. Os dados do ensaio cl\u00ednico de Fase II para o Retatrutide reportaram uma redu\u00e7\u00e3o de peso de at\u00e9 24% \u00e0s 48 semanas \u2014 superando os resultados tanto do Tirzepatide como do Semaglutide em per\u00edodos compar\u00e1veis. Acredita-se que a atividade adicional no receptor de glucagon promova um maior gasto energ\u00e9tico e oxida\u00e7\u00e3o de gordura. <\/p>\n<h3>Posso encomendar Retatrutide para envio internacional?<\/h3>\n<p>Sim. A MedsBase envia Retatrutide para todo o mundo a partir da nossa rede dedicada de envio de p\u00e9ptidos. As encomendas exclusivas de p\u00e9ptidos qualificam-se para o nosso servi\u00e7o de envio de p\u00e9ptidos aut\u00f3nomo. As encomendas s\u00e3o enviadas em embalagens com controlo de temperatura e com rastreio completo. <!-- medsbase-related-alts-v1 --><\/p>\n<h2>Other Peptides for Recovery and Performance<\/h2>\n<ul>\n<li><a href=\"\/pt-pt\/bpc-157\/\"><strong>BPC-157<\/strong><\/a> \u2014 Body Protection Compound \u2014 tendon, ligament, gut recovery<\/li>\n<li><a href=\"\/pt-pt\/tb-500\/\"><strong>TB-500<\/strong><\/a> \u2014 Thymosin Beta-4 fragment \u2014 soft tissue and vascular recovery<\/li>\n<li><a href=\"\/pt-pt\/ipamorelin\/\"><strong>Ipamorelin<\/strong><\/a> \u2014 Agonista selectivo de grelina \u2014 pulso de GH limpo sem cortisol\/prolactina<\/li>\n<li><a href=\"\/pt-pt\/cjc-1295-with-dac\/\"><strong>CJC-1295 com DAC<\/strong><\/a> \u2014 An\u00e1logo de GHRH com meia-vida prolongada<\/li>\n<li><a href=\"\/pt-pt\/ghk-cu\/\"><strong>GHK-Cu<\/strong><\/a> \u2014 Copper peptide \u2014 skin and connective tissue regeneration<\/li>\n<\/ul>\n<p><!-- medsbase-peptide-guide-cta --><\/p>\n<h2>Leitura Adicional<\/h2>\n<div style=\"background: #f4f8fb; border-left: 4px solid #2c7cb0; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<p style=\"margin: 0 0 8px 0;\"><strong>\ud83d\udcd6 Learn the science behind this peptide<\/strong><\/p>\n<p style=\"margin: 0;\">Leia o nosso guia completo baseado em evid\u00eancias: <a href=\"https:\/\/medsbase.com\/pt-pt\/retatrutide-triple-agonist-weight-loss-guide\/\"><strong>Retatrutide \u2014 mecanismo, dados de ensaios e perspetivas<\/strong><\/a>. Covers mechanism of action, published study data, typical dosing ranges, reconstitution protocols, stacking considerations, and safety\/contraindication notes.<\/p>\n<\/div>\n<p><!-- pep-seo-v1 --><\/p>","protected":false},"excerpt":{"rendered":"<p>\u2705 Apoia a perda de peso saud\u00e1vel e melhora a fun\u00e7\u00e3o metab\u00f3lica<br data-start=\"62\" data-end=\"65\" \/>\u2705 Ajuda a regular o equil\u00edbrio energ\u00e9tico para um melhor desempenho di\u00e1rio<br data-start=\"125\" data-end=\"128\" \/>\u2705 Promove uma maior queima de gordura e efici\u00eancia metab\u00f3lica<br data-start=\"184\" data-end=\"187\" \/>\u2705 Auxilia no controlo do apetite e reduz os desejos<br data-start=\"239\" data-end=\"242\" \/>\u2705 Promove melhores resultados globais na gest\u00e3o do peso<\/p>\n<p><strong>Retatrutide<\/strong> cont\u00e9m composto de p\u00e9ptido sint\u00e9tico.<\/p>","protected":false},"featured_media":70975,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[5426],"product_tag":[5445,5444,5447,5446],"class_list":["post-68772","product","type-product","status-publish","has-post-thumbnail","product_cat-peptides","product_tag-ly3437943","product_tag-retatrutide","product_tag-triple-agonist","product_tag-triple-g","first","instock","shipping-taxable","purchasable","product-type-variable","has-default-attributes"],"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/product\/68772","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/comments?post=68772"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/media\/70975"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/media?parent=68772"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/product_brand?post=68772"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/product_cat?post=68772"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/product_tag?post=68772"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}